Brief: Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche

Lisata Therapeutics

10/08/2022 13:37

Aug 10 (Reuters) - Caladrius Biosciences Inc  CLBS.O :
    * CALADRIUS BIOSCIENCES’ PROSPECTIVE MERGER PARTNER, CEND
THERAPEUTICS, ANNOUNCES COLLABORATION AGREEMENT WITH ROCHE TO
EVALUATE CEND-1 IN COMBINATION WITH IMMUNOTHERAPY TO TREAT
PANCREATIC CANCER
    * CALADRIUS BIOSCIENCES INC - AGREEMENT ACCELERATED BY
CALADRIUS'
INITIAL INVESTMENT IN CEND
    * CALADRIUS- ROCHE WILL BE RESPONSIBLE FOR OPERATIONAL
MANAGEMENT
OF TRIAL WHILE CEND AND ROCHE SHARE EQUALLY IN COSTS OF CEND-1
TREATMENT ARMS IN STUDY

Source text for Eikon:  ID:nGNX4kTY3g 
Further company coverage:  CLBS.O 

 ((reuters.briefs@thomsonreuters.com;))